Skip Navigation
Skip to contents
Results by Year

View Wide

Filter

ARTICLE TYPE

more+
SELECT FILTER
 
Close

PUBLICATION DATE

380 results
Display

New biomarkers of hepatitis B virus (HBV) infection: HBV RNA and HBV core-related antigen, new kids on the block?

Lim YS

CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Moving toward hepatitis B virus functional cure - the impact of on-treatment kinetics of serum viral markers

Liang LY, Wong VWS, Wong GLH, Yip TCF

CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Report on the External Quality Assessment Scheme for Molecular Microbiology, Hepatitis Virus 1, 2 (2016–2021)

Moon HW, Lee TH, Seo JD

The clinical demand for molecular tests is increasing and thus, the need for quality control is also increasing. The Korean Association of External Quality Assessment Service has operated a test...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Updated Treatment Guidelines for Chronic Hepatitis B

An J

Chronic hepatitis B virus (HBV) infection is a major cause of liver cirrhosis and hepatocellular carcinoma in Korea. While the prevalence of HBV infection is gradually declining in Korea, 3...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Decreased vitamin D-binding protein level portends poor outcome in acute-on-chronic liver failure caused by hepatitis B virus

Wu D, Rao Q, Xie Z, Zhu X, Che Y, Wu J, Gao H, Zhang J, Hou Z, Cheng X, Sun Z

Background/Aims: Acute-on-chronic liver failure (ACLF) is a catastrophic illness. Few studies investigated the prognostic value of vitamin D-binding protein (VDBP) for hepatitis B virus (HBV)-related ACLF (HBV-ACLF) resulted in conflicting...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
RNA interference as a novel treatment strategy for chronic hepatitis B infection

Hui RWH, Mak LY, Seto WK, Yuen MF

Chronic hepatitis B (CHB) is a major cause of liver-related morbidity and mortality. Functional cure of CHB, defined as sustainable hepatitis B surface antigen (HBsAg) seroclearance, is associated with improved...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Risk of Hepatitis B Virus (HBV) Reactivation in Patients with Immune-Mediated Inflammatory Diseases Receiving Biologics: Focus on the Timing of Biologics after Anti-HBV Treatment

Ahn SM, Choi J, Ye BD, Yang SK, Oh JS, Kim Y, Lee C, Yoo B, Park SH, Hong S

Background/Aims: Anti-hepatitis B virus (HBV) therapy is required for patients with HBV infection receiving biologics because of the high risk of HBV reactivation. However, it is unclear when to start...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Metabolic Risk Factors Are Associated with the Disease Severity and Prognosis of Hepatitis B Virus-Related Acute on Chronic Liver Failure

Chen L, Dai J, Xie Q, Wang X, Cai W

Background/Aims: Metabolic risk factors could accelerate hepatitis B virus (HBV)-related mortality; however, their impacts on disease severity in HBV-related acute on chronic liver failure (HBV-ACLF) patients remain unexplored. In this...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Clinical Course of Hepatitis B Viral Infection in Patients Undergoing Anti-Tumor Necrosis Factor α Therapy for Inflammatory Bowel Disease

Lee JM, Wei SC, Lee KM, Ye BD, Mao R, Kim HS, Park SJ, Park SH, Oh EH, Im JP, Jang BI, Kim DB, Takeuchi K

Background/Aims: Little is known about the clinical course of hepatitis B virus (HBV)-infected patients undergoing anti-tumor necrosis factor α (TNF-α) therapy for inflammatory bowel disease (IBD). We aimed to investigate...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
A Multi-Center, Double-Blind Randomized Controlled Phase III Clinical Trial to Evaluate the Antiviral Activity and Safety of DA-2802 (Tenofovir Disoproxil Orotate) and Viread (Tenofovir Disoproxil Fumarate) in Chronic Hepatitis B Patients

Kim HJ, Kim JH, Yeon JE, Seo YS, Jang JW, Cho YK, Jang BK, Han BH, Lee C, Lee JH, Yoon JH, Kim KM, Kim MY, Kim DY, Park NH, Cho EY, Lee JS, Lee JW, Kim IH, Song BC, Lee BS, Kwon OS

Background: Tenofovir disoproxil fumarate (TDF, Viread® ) had been used as a standard treatment option of chronic hepatitis B (CHB). This clinical trial was conducted to evaluate the efficacy and...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Identification of key genes and carcinogenic pathways in hepatitis B virus-associated hepatocellular carcinoma through bioinformatics analysis

Kim SH, Hwang S, Song GW, Jung DH, Moon DB, Yang JD, Yu HC

Backgrounds/Aims: Mechanisms for the development of hepatocellular carcinoma (HCC) in hepatitis B virus (HBV)-infected patients remain unclear. The aim of the present study was to identify genes and pathways involved...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Protectivity and safety following recombinant hepatitis B vaccine with different source of bulk compared to hepatitis B (Bio Farma) vaccine in Indonesia

Nency YM, Rahmadi FA, M, Anantyo DT, Farhanah N, Hapsari R, Farida H, Sadhana U, Djagat H, Kristina TN, Juniarto AZ, Puspita M, Sari RM, Bachtiar NS

Purpose Indonesia, a high populous and the second-highest country in epidemicity of hepatitis B in South-East Asia require maintaining its capacity of monovalent hepatitis B production to keep up with both...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Hepatocellular carcinoma and cancer-related mortality after kidney transplantation with rituximab treatment

Lee H, Kim YH, Lim SJ, Ko Y, Shin S, Jung JH, Baek C, Kim H, Park SK, Kwon H

Purpose: There are increased therapeutic usages of rituximab in kidney transplantation (KT). However, few studies have evaluated the effect of rituximab on cancer development following KT. This study aimed to...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Toward a complete cure for chronic hepatitis B: Novel therapeutic targets for hepatitis B virus

Kim SW, Yoon JS, Lee M, Cho Y

Hepatitis B virus (HBV) affects approximately 250 million patients worldwide, resulting in the progression to cirrhosis and hepatocellular carcinoma, which are serious public health problems. Although universal vaccination programs exist,...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Hepatitis B virus X Protein Promotes Liver Cancer Progression through Autophagy Induction in Response to TLR4 Stimulation

Hepatitis B virus X (HBx) protein has been reported as a key protein regulating the pathogenesis of HBV-induced hepatocellular carcinoma (HCC). Recent evidence has shown that HBx is implicated in...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Hepatitis B virus X Protein Promotes Liver Cancer Progression through Autophagy Induction in Response to TLR4 Stimulation

Hepatitis B virus X (HBx) protein has been reported as a key protein regulating the pathogenesis of HBV-induced hepatocellular carcinoma (HCC). Recent evidence has shown that HBx is implicated in...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Hepatitis B virus X Protein Promotes Liver Cancer Progression through Autophagy Induction in Response to TLR4 Stimulation

Son J, Kim MJ, Lee JS, Kim JY, Chun E, Lee KY

Hepatitis B virus X (HBx) protein has been reported as a key protein regulating the pathogenesis of HBV-induced hepatocellular carcinoma (HCC). Recent evidence has shown that HBx is implicated in...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
History and future of hepatitis B virus control in South Korea

Kim DY

CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Cost-effectiveness and long-term outcomes of liver transplantation using hepatitis B core antibody-positive grafts with hepatitis B immunoglobulin prophylaxis in Korea

Kim KD, Lee JE, Kim JM, Lee O, Hwang NY, Rhu J, Choi GS, Kim K, Joh JW

Background/Aims: Hepatitis B core antibody (anti-HBc)-positive donors are used as an extended donor pool, and current guidelines recommend the usage of nucleos(t)ide analogues (NAs) as prophylaxis for preventing de novo...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Three heads are better than two: Hepatitis B core-related antigen as a new predictor of hepatitis B virus-related hepatocellular carcinoma

Wu JW, Kao JH, Tseng TC

Patients with chronic hepatitis B virus (HBV) infection are at risk of developing hepatocellular carcinoma (HCC), and serum markers reflecting viral replication are potential predictors for HCC development. Besides the...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close

Go to Top

Copyright © 2023 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr